Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects

Dmitriy Sheyn, Shiran Ben-David, Galina Shapiro, Sandra de Mel, Maxim Bez, Loren Ornelas, Anais Sahabian, Dhruv Sareen, Xiaoyu Da, Gadi Pelled, Wafa Tawackoli, Zhenqiu Liu, Dan Gazit, Zulma Gazit

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) are currently the most established cells for skeletal tissue engineering and regeneration; however, their availability and capability of self-renewal are limited. Recent discoveries of somatic cell reprogramming may be used to overcome these challenges. Wehypothesized that induced pluripotent stem cells (iPSCs) that were differentiated into MSCs could be used for bone regeneration. Short-term exposure of embryoid bodies to transforming growth factor-β was used to direct iPSCs toward MSC differentiation. During this process, two types of iPSC-derived MSCs (iMSCs) were identified: early (aiMSCs) and late (tiMSCs) outgrowing cells. The transition of iPSCs toward MSCs was documented using MSC marker flow cytometry. Both types of iMSCs differentiated in vitro in response to osteogenic or adipogenic supplements. The results of quantitative assays showed that both cell types retained their multidifferentiation potential, although aiMSCs demonstrated higher osteogenic potential than tiMSCs and bone marrow-derived MSCs (BM-MSCs). Ectopic injections of BMP6-overexpressing tiMSCs produced no or limited bone formation, whereas similar injections of BMP6-overexpressing aiMSCs resulted in substantial bone formation. Upon orthotopic injection into radial defects, all three cell types regenerated bone and contributed to defect repair. In conclusion, MSCs can be derived from iPSCs and exhibit self-renewal without tumorigenic ability. Compared with BM-MSCs, aiMSCs acquire more of a stem cell phenotype, whereas tiMSCs acquire more of a differentiated osteoblast phenotype, which aids bone regeneration but does not allow the cells to induce ectopic bone formation (even when triggered by bone morphogenetic proteins), unless in an orthotopic site of bone fracture.

Original languageEnglish (US)
Pages (from-to)1447-1460
Number of pages14
JournalStem Cells Translational Medicine
Volume5
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Induced Pluripotent Stem Cells
Mesenchymal Stromal Cells
Bone and Bones
Osteogenesis
Bone Regeneration
Injections
Bone Marrow
Embryoid Bodies
Phenotype
Bone Morphogenetic Proteins
Bone Fractures
Transforming Growth Factors
Tissue Engineering
Osteoblasts
Regeneration
Cell Differentiation
Flow Cytometry
Stem Cells

All Science Journal Classification (ASJC) codes

  • Developmental Biology
  • Cell Biology

Cite this

Sheyn, Dmitriy ; Ben-David, Shiran ; Shapiro, Galina ; de Mel, Sandra ; Bez, Maxim ; Ornelas, Loren ; Sahabian, Anais ; Sareen, Dhruv ; Da, Xiaoyu ; Pelled, Gadi ; Tawackoli, Wafa ; Liu, Zhenqiu ; Gazit, Dan ; Gazit, Zulma. / Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects. In: Stem Cells Translational Medicine. 2016 ; Vol. 5, No. 11. pp. 1447-1460.
@article{cac7bf51c8ac4dde95ec77788fb1b7e0,
title = "Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects",
abstract = "Mesenchymal stem cells (MSCs) are currently the most established cells for skeletal tissue engineering and regeneration; however, their availability and capability of self-renewal are limited. Recent discoveries of somatic cell reprogramming may be used to overcome these challenges. Wehypothesized that induced pluripotent stem cells (iPSCs) that were differentiated into MSCs could be used for bone regeneration. Short-term exposure of embryoid bodies to transforming growth factor-β was used to direct iPSCs toward MSC differentiation. During this process, two types of iPSC-derived MSCs (iMSCs) were identified: early (aiMSCs) and late (tiMSCs) outgrowing cells. The transition of iPSCs toward MSCs was documented using MSC marker flow cytometry. Both types of iMSCs differentiated in vitro in response to osteogenic or adipogenic supplements. The results of quantitative assays showed that both cell types retained their multidifferentiation potential, although aiMSCs demonstrated higher osteogenic potential than tiMSCs and bone marrow-derived MSCs (BM-MSCs). Ectopic injections of BMP6-overexpressing tiMSCs produced no or limited bone formation, whereas similar injections of BMP6-overexpressing aiMSCs resulted in substantial bone formation. Upon orthotopic injection into radial defects, all three cell types regenerated bone and contributed to defect repair. In conclusion, MSCs can be derived from iPSCs and exhibit self-renewal without tumorigenic ability. Compared with BM-MSCs, aiMSCs acquire more of a stem cell phenotype, whereas tiMSCs acquire more of a differentiated osteoblast phenotype, which aids bone regeneration but does not allow the cells to induce ectopic bone formation (even when triggered by bone morphogenetic proteins), unless in an orthotopic site of bone fracture.",
author = "Dmitriy Sheyn and Shiran Ben-David and Galina Shapiro and {de Mel}, Sandra and Maxim Bez and Loren Ornelas and Anais Sahabian and Dhruv Sareen and Xiaoyu Da and Gadi Pelled and Wafa Tawackoli and Zhenqiu Liu and Dan Gazit and Zulma Gazit",
year = "2016",
month = "11",
day = "1",
doi = "10.5966/sctm.2015-0311",
language = "English (US)",
volume = "5",
pages = "1447--1460",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "11",

}

Sheyn, D, Ben-David, S, Shapiro, G, de Mel, S, Bez, M, Ornelas, L, Sahabian, A, Sareen, D, Da, X, Pelled, G, Tawackoli, W, Liu, Z, Gazit, D & Gazit, Z 2016, 'Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects', Stem Cells Translational Medicine, vol. 5, no. 11, pp. 1447-1460. https://doi.org/10.5966/sctm.2015-0311

Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects. / Sheyn, Dmitriy; Ben-David, Shiran; Shapiro, Galina; de Mel, Sandra; Bez, Maxim; Ornelas, Loren; Sahabian, Anais; Sareen, Dhruv; Da, Xiaoyu; Pelled, Gadi; Tawackoli, Wafa; Liu, Zhenqiu; Gazit, Dan; Gazit, Zulma.

In: Stem Cells Translational Medicine, Vol. 5, No. 11, 01.11.2016, p. 1447-1460.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Human induced pluripotent stem cells differentiate into functional mesenchymal stem cells and repair bone defects

AU - Sheyn, Dmitriy

AU - Ben-David, Shiran

AU - Shapiro, Galina

AU - de Mel, Sandra

AU - Bez, Maxim

AU - Ornelas, Loren

AU - Sahabian, Anais

AU - Sareen, Dhruv

AU - Da, Xiaoyu

AU - Pelled, Gadi

AU - Tawackoli, Wafa

AU - Liu, Zhenqiu

AU - Gazit, Dan

AU - Gazit, Zulma

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Mesenchymal stem cells (MSCs) are currently the most established cells for skeletal tissue engineering and regeneration; however, their availability and capability of self-renewal are limited. Recent discoveries of somatic cell reprogramming may be used to overcome these challenges. Wehypothesized that induced pluripotent stem cells (iPSCs) that were differentiated into MSCs could be used for bone regeneration. Short-term exposure of embryoid bodies to transforming growth factor-β was used to direct iPSCs toward MSC differentiation. During this process, two types of iPSC-derived MSCs (iMSCs) were identified: early (aiMSCs) and late (tiMSCs) outgrowing cells. The transition of iPSCs toward MSCs was documented using MSC marker flow cytometry. Both types of iMSCs differentiated in vitro in response to osteogenic or adipogenic supplements. The results of quantitative assays showed that both cell types retained their multidifferentiation potential, although aiMSCs demonstrated higher osteogenic potential than tiMSCs and bone marrow-derived MSCs (BM-MSCs). Ectopic injections of BMP6-overexpressing tiMSCs produced no or limited bone formation, whereas similar injections of BMP6-overexpressing aiMSCs resulted in substantial bone formation. Upon orthotopic injection into radial defects, all three cell types regenerated bone and contributed to defect repair. In conclusion, MSCs can be derived from iPSCs and exhibit self-renewal without tumorigenic ability. Compared with BM-MSCs, aiMSCs acquire more of a stem cell phenotype, whereas tiMSCs acquire more of a differentiated osteoblast phenotype, which aids bone regeneration but does not allow the cells to induce ectopic bone formation (even when triggered by bone morphogenetic proteins), unless in an orthotopic site of bone fracture.

AB - Mesenchymal stem cells (MSCs) are currently the most established cells for skeletal tissue engineering and regeneration; however, their availability and capability of self-renewal are limited. Recent discoveries of somatic cell reprogramming may be used to overcome these challenges. Wehypothesized that induced pluripotent stem cells (iPSCs) that were differentiated into MSCs could be used for bone regeneration. Short-term exposure of embryoid bodies to transforming growth factor-β was used to direct iPSCs toward MSC differentiation. During this process, two types of iPSC-derived MSCs (iMSCs) were identified: early (aiMSCs) and late (tiMSCs) outgrowing cells. The transition of iPSCs toward MSCs was documented using MSC marker flow cytometry. Both types of iMSCs differentiated in vitro in response to osteogenic or adipogenic supplements. The results of quantitative assays showed that both cell types retained their multidifferentiation potential, although aiMSCs demonstrated higher osteogenic potential than tiMSCs and bone marrow-derived MSCs (BM-MSCs). Ectopic injections of BMP6-overexpressing tiMSCs produced no or limited bone formation, whereas similar injections of BMP6-overexpressing aiMSCs resulted in substantial bone formation. Upon orthotopic injection into radial defects, all three cell types regenerated bone and contributed to defect repair. In conclusion, MSCs can be derived from iPSCs and exhibit self-renewal without tumorigenic ability. Compared with BM-MSCs, aiMSCs acquire more of a stem cell phenotype, whereas tiMSCs acquire more of a differentiated osteoblast phenotype, which aids bone regeneration but does not allow the cells to induce ectopic bone formation (even when triggered by bone morphogenetic proteins), unless in an orthotopic site of bone fracture.

UR - http://www.scopus.com/inward/record.url?scp=84992157000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992157000&partnerID=8YFLogxK

U2 - 10.5966/sctm.2015-0311

DO - 10.5966/sctm.2015-0311

M3 - Article

AN - SCOPUS:84992157000

VL - 5

SP - 1447

EP - 1460

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 11

ER -